Khosro Keshavarz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5161642/publications.pdf

Version: 2024-02-01

1039406 996533 43 287 9 15 citations g-index h-index papers 58 58 58 427 times ranked citing authors docs citations all docs

#	Article	IF	CITATIONS
1	Cost-Effectiveness Analysis of Different Methods of Treatment of Tubal Ectopic Pregnancy in the South of Iran. Value in Health Regional Issues, 2022, 28, 90-97.	0.5	O
2	Economic burden of multiple sclerosis: a cross-sectional study in Iran. Health Economics Review, 2022, 12, 2.	0.8	1
3	Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. BMC Health Services Research, 2022, 22, 118.	0.9	5
4	Is it Effective and Cost-saving to Send all Tonsillectomy Specimens for Histopathological Examinations?. Iranian Journal of Otorhinolaryngology, 2022, 34, 35-44.	0.4	0
5	Cost-Effectiveness Analysis of Intraoperative Frozen Section in Women with Breast Cancer: Evidence from South of Iran Iranian Journal of Medical Sciences, 2022, 47, 143-151.	0.3	O
6	Cost-effectiveness analysis of hearing screening program for primary school children in southern Iran, Shiraz. BMC Pediatrics, 2022, 22, .	0.7	1
7	A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran. Hematology, 2021, 26, 240-248.	0.7	1
8	The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran. BMC Health Services Research, 2021, 21, 132.	0.9	80
9	Economic Viability and Efficacy of Day Case Versus Inpatient Tonsillectomy in Southern Iran. Value in Health Regional Issues, 2021, 24, 193-198.	0.5	1
10	The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke. Stroke Research and Treatment, 2021, 2021, 1-8.	0.5	1
11	Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. BioMed Research International, 2021, 2021, 1-12.	0.9	11
12	Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C. Hepatitis Monthly, 2021, 21, .	0.1	0
13	Lessons from one year experience of pooled procurement of pharmaceuticals: exploration of indicators and assessing pharmacies` performance. DARU, Journal of Pharmaceutical Sciences, 2020, 28, 13-23.	0.9	4
14	Selective serotonin reuptake inhibitors in major depression disorder treatment: an umbrella review on systematic reviews. International Journal of Psychiatry in Clinical Practice, 2020, 24, 357-370.	1.2	13
15	Effect of two major health reforms on health care cost and utilization in Fars Province of Iran: family physician program and health transformation plan. BMC Health Services Research, 2020, 20, 382.	0.9	12
16	Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A. DARU, Journal of Pharmaceutical Sciences, 2020, 28, 287-293.	0.9	1
17	Economic burden of hemophilia A and B: a case in Iran. Hematology, 2020, 25, 149-155.	0.7	3
18	Deductibles in Health Insurance, Beneficial or Detrimental: A Review Article. Iranian Journal of Public Health, 2020, 49, 851-859.	0.3	1

#	Article	IF	CITATIONS
19	Positron Emission Mammography (PEM) in the diagnosis of breast cancer: A systematic review and economic evaluation. Medical Journal of the Islamic Republic of Iran, 2020, 34, 100.	0.9	0
20	Evaluation of the effectiveness of infusion of bone marrow derived cell in patients with heart failure: A network meta-analysis of randomized clinical trials and cohort studies. Medical Journal of the Islamic Republic of Iran, 2020, 34, 178.	0.9	0
21	Can Health be Related to Interpersonal Violence in Middle Eastern Countries?. Archives of Iranian Medicine, 2020, 23, 84-89.	0.2	0
22	Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. Journal of Medical Economics, 2019, 22, 297-305.	1.0	10
23	Estimating the Cost of Illness of Prostate Cancer in Iran. Clinical Therapeutics, 2019, 41, 50-58.	1.1	13
24	Cost-Effectiveness Analysis of Topiramate versus Phenobarbital in the Treatment of Children with Febrile Seizure. Iranian Journal of Child Neurology, 2019, 13, 109-120.	0.2	2
25	Tenecteplase Versus Reteplase in Acute Myocardial Infarction: A Network Meta-Analysis of Randomized Clinical Trials. Iranian Journal of Pharmaceutical Research, 2019, 18, 1622-1631.	0.3	0
26	Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. Hematology, 2018, 23, 417-422.	0.7	3
27	Cost - effectiveness and Cost - utility of CinnoVex versus ReciGen in Patients with Relapsing - Remitting Multiple Sclerosis in Iran. Shiraz E Medical Journal, 2018, In Press, .	0.1	2
28	Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials. DARU, Journal of Pharmaceutical Sciences, 2017, 25, 23.	0.9	11
29	Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin's Lymphoma: A Cost-Effectiveness Study. Asian Pacific Journal of Cancer Prevention, 2017, 18, 2703-2707.	0.5	2
30	Factors Affecting the Utilization of Outpatient Health Services and Importance of Health Insurance. Shiraz E Medical Journal, 2017, 18, .	0.1	5
31	Economic Burden of Scorpion Sting and Snake Bite from a Social Perspective in Iran. Shiraz E Medical Journal, 2017, 18, .	0.1	7
32	Social accounting matrix and the effects of economic reform on health price index and household expenditures: Evidence from Iran. Medical Journal of the Islamic Republic of Iran, 2017, 31, 391-395.	0.9	0
33	Cost-Effectiveness Analysis of the Unfractionated Heparin versus Low-Molecular-Weight Heparin in Hospitalized Patients with Stroke Due to Atrial Fibrillation in Shiraz, South of Iran. Journal of Vascular and Interventional Neurology, 2017, 9, 6-12.	1.1	3
34	A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Iranian Red Crescent Medical Journal, 2016, 18, e37094.	0.5	9
35	A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model. Hepatitis Monthly, 2016, 16, e37435.	0.1	7
36	Is Taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost- effectiveness analysis. Medical Journal of the Islamic Republic of Iran, 2016, 30, 347.	0.9	7

#	Article	lF	CITATIONS
37	Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran. Hepatitis Monthly, 2015, 15, e25854.	0.1	33
38	Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer. Archives of Medical Science, 2013, 3, 472-478.	0.4	5
39	Systematic review/Meta-analysis A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience. Archives of Medical Science, 2013, 6, 961-967.	0.4	8
40	Pharmacists remuneration models in iran and selected countries: a comparative study. Iranian Journal of Pharmaceutical Research, 2013, 12, 995-64.	0.3	10
41	Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?. DARU, Journal of Pharmaceutical Sciences, 2012, 20, 62.	0.9	9
42	The Effectiveness and Cost-effectiveness of Pregabalin in the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review and Economic Model. International Journal of Pharmacology, 2012, 8, 490-495.	0.1	3
43	Cost-Effectiveness Analysis of Group vs. Weblog Telecommunication (Web Tel) Nutrition Education Program on Glycemic Indices in Patients With Non-Insulin Dependent Diabetes Mellitus Type 2: A Randomized Controlled Trial. Frontiers in Nutrition, 0, 9, .	1.6	1